All News

The CDC said clinicians should be aware of these trends, select treatments carefully, and strengthen prevention efforts.

Your daily dose of the clinical news you may have missed.

Patient Care tapped the rich trove of research and expert perspectives from the Revolutionizing Atopic Dermatitis 2025 conference to create a snapshot of the AD care of the future.

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

A study of more than 559 000 adults and 2.4 million genetic samples found that alcohol consumption of any amount increases dementia risk, challenging prior evidence of protective effects from light drinking.

The FDA has initiated approval of leucovorin calcium tablets for children with cerebral folate deficiency, which can manifest with autistic features. What is it?

New data will be shared from the PATHFINDER 2 study in asymptomatic patients and the SYMPLIFY study in patients experiencing symptoms.

Your daily dose of the clinical news you may have missed.

PODCAST: Family physician Ada Stewart, MD, shares practical strategies for cervical cancer screening and patient communication.

The findings highlight rezpegaldesleukin's novel broad-based Treg mechanism, suggesting it may be a potent option with potential for disease modification in atopic dermatitis.

The administration has initiated a nationwide public service campaign about the potential risks as professional societies quickly disputed the claims.

Your daily dose of the clinical news you may have missed.

Michael Crotty, MD, an expert in obesity medicine, discusses GLP-1RAs in the context of weight loss, including the novel dual agonist survodutide.

EADV 2025: Guttman-Yassky has great confidence in the future of agents that block the OX40 pathway, suggesting that they have the potential for disease modification.

Seniors remain protected along with any adult or child with underlying risk factors for severe disease, but the healthy US population is left with a choice, so far.

Corticosteroids following resolution of anaphylaxis should be chosen with clear, clinical rationale and reserved for select children, study authors concluded.

The new study, based in China, will validate urine-based genetic methylation testing which concentrates trace amounts of HPV DNA by more than 10,000 times.

FDA approves guselkumab as the first fully subcutaneous IL-23 inhibitor for ulcerative colitis, showing significant clinical benefits in trials.